$5.86
8.32% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Solid Biosciences Inc. Stock price

$5.86
+0.15 2.63% 1M
-1.93 24.78% 6M
-0.28 4.56% YTD
+2.78 90.26% 1Y
-24.89 80.94% 3Y
-55.49 90.45% 5Y
-333.44 98.27% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.45 8.32%
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Key metrics

Market capitalization $234.13m
Enterprise Value $87.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.37
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-112.10m
Free Cash Flow (TTM) Free Cash Flow $-91.73m
Cash position $171.12m
EPS (TTM) EPS $-3.04
P/E forward negative
Short interest 7.80%
Show more

Is Solid Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Solid Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Solid Biosciences Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Solid Biosciences Inc. forecast:

Buy
100%

Financial data from Solid Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 2.55 2.55
12% 12%
-
-2.55 -2.55
12% 12%
-
- Selling and Administrative Expenses 26 26
14% 14%
-
- Research and Development Expense 81 81
2% 2%
-
-110 -110
1% 1%
-
- Depreciation and Amortization 2.55 2.55
12% 12%
-
EBIT (Operating Income) EBIT -112 -112
1% 1%
-
Net Profit -102 -102
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Solid Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Solid Biosciences Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, No...
Neutral
GlobeNewsWire
20 days ago
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
Neutral
GlobeNewsWire
about 2 months ago
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired employees.
More Solid Biosciences Inc. News

Company Profile

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Cumbo
Employees 88
Founded 2013
Website www.solidbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today